SPASMOPYRALGIN-M — SUGAR-COATED TABLETS

ANALGIN 255 MG + CAMYLOFIN 25 MG

Product Overview

SPASMOPYRALGIN-M is a combination analgesic and antispasmodic medication formulated to relieve pain associated with smooth muscle spasms. It combines Analgin (Metamizole) 255 mg, which provides analgesic and antipyretic effects, with Camylofin 25 mg, an antispasmodic agent that helps relax smooth muscles and relieve painful spasms.

This combination is particularly indicated for the symptomatic relief of severe colicky pain, including biliary and renal colic, as well as menstrual cramps (dysmenorrhea).

Active Ingredients & Mechanism of Action

1. Analgin (Metamizole) – 255 mg

• Provides analgesic effects to help relieve moderate to severe pain.
• Has antipyretic properties that help reduce fever.
• Also possesses antispasmodic activity, contributing to relief of painful visceral conditions.

2. Camylofin – 25 mg

• Acts as an antispasmodic agent.
• Helps relax smooth muscles in the gastrointestinal and genitourinary tracts.
• Reduces painful spasms and cramping associated with smooth muscle contractions.

The combination provides complementary pain-relieving and antispasmodic effects.

Indications & Therapeutic Uses

SPASMOPYRALGIN-M is indicated for symptomatic relief of:

• Biliary Colic: Helps relieve pain associated with spasms of the biliary tract.
• Renal Colic: Helps alleviate painful spasms associated with renal colic.
• Dysmenorrhea: Helps relieve menstrual pain and uterine cramping.
• Visceral Spasmodic Pain: Provides combined analgesic and antispasmodic effects for painful smooth muscle spasms.

These uses are consistent with the indications stated on the supplied product packaging.

Recommended Dosage & Administration

• Use according to the prescribed dosage and your healthcare professional's instructions.
• Swallow the sugar-coated tablet with sufficient water.
• Do not exceed the prescribed dose or duration of treatment.
• Use the lowest effective dose for the shortest appropriate period.

Note: The supplied packaging does not specify a dosage schedule; therefore, dosing should follow the approved product leaflet or medical prescription.

Warnings & Precautions

• Blood disorders: Metamizole may rarely cause agranulocytosis, a serious reduction in white blood cells that can increase the risk of life-threatening infections.
• Stop treatment and seek immediate medical attention if fever, chills, sore throat, or painful mouth or mucosal ulcers develop.
• Avoid use in patients with a history of metamizole-induced agranulocytosis, bone marrow disorders, or significant blood-forming system abnormalities.
• Use cautiously in patients with impaired kidney or liver function.
• Patients with low blood pressure or a history of allergic reactions to analgesics should consult their physician before use.
• Camylofin may cause anticholinergic effects; caution is required in patients with glaucoma, urinary retention, or gastrointestinal obstruction.
• Avoid combining with other metamizole-containing medications unless specifically prescribed.
• Pregnancy and breastfeeding: Metamizole-containing medicines are contraindicated during pregnancy and breastfeeding according to Egyptian Drug Authority safety guidance.
• Keep out of reach of children.

Possible Side Effects

Common or less serious adverse effects may include:

• Nausea and gastrointestinal discomfort.
• Dry mouth.
• Dizziness or headache.
• Constipation.
• Palpitations or increased heart rate.
• Blurred vision.

Serious but uncommon adverse effects include:

• Agranulocytosis and other blood disorders.
• Severe allergic reactions, including anaphylaxis.
• Significant hypotension.
• Severe skin reactions.
• Liver or kidney injury.

Storage Conditions

• Store in the original packaging.
• Keep in a dry place, away from direct sunlight and excessive heat.
• Keep out of reach of children.
• Follow the storage instructions printed on the package.

Pack Information

• Dosage form: Sugar-coated tablets.
• Active ingredients: Analgin 255 mg + Camylofin 25 mg per tablet.
• Pack presentation: 3 strips × 10 tablets.
• Total pack size: 30 sugar-coated tablets.
• Manufacturer: Kahira Pharmaceuticals & Chemical Industries.

References

1. European Medicines Agency (EMA) – Metamizole-containing medicinal products: safety recommendations and risk of agranulocytosis. EMA – Metamizole Safety Review.
2. Egyptian Drug Authority (EDA) – Direct Healthcare Professional Communication regarding metamizole and contraindications during pregnancy and breastfeeding. EDA – Metamizole Safety Communication.
3. National Institutes of Health (NIH) – LiverTox: Metamizole (Dipyrone), including adverse effects and potential liver injury. NIH – Metamizole Monograph.
4. International Journal of Reproduction, Contraception, Obstetrics and Gynecology – Camylofin Dihydrochloride Injection: A Drug Monograph Review, covering pharmacology, antispasmodic effects, safety, and clinical applications. Camylofin Drug Monograph.
5. National Center for Biotechnology Information (NCBI) – Muscarinic Antagonists: pharmacological actions, adverse effects, and contraindications relevant to anticholinergic antispasmodics. NCBI – Muscarinic Antagonists.
6. European Directorate for the Quality of Medicines (EDQM) – Evidence-based review of metamizole combinations and their therapeutic profiles. EDQM – Therapeutic Profile.

Patient Disclaimer

This medication should be used under the supervision of a qualified healthcare professional. The information provided is intended for educational purposes only and does not replace professional medical advice, diagnosis, or treatment. Always follow the prescribed dosage and consult your doctor or pharmacist before use, especially if you have an existing medical condition, take other medications, or are pregnant or breastfeeding.

►Important safety note: Metamizole-associated agranulocytosis can occur at any time during treatment, even in patients who have previously used the medicine without problems. Recognizing early warning symptoms and seeking immediate medical attention is essential.